NR1H2: A Nuclear Receptor Linked To Cellular Signaling and Disease

Target Name: NR1H2

NCBI ID: G7376

NR1H2

NR1H2: A Nuclear Receptor Linked To Cellular Signaling and Disease

Nuclear receptor LXR-beta (NR1H2) is a protein that plays a crucial role in cellular signaling. It is a nuclear receptor that is expressed in various tissues and cells throughout the body. One of its main functions is to regulate the expression of other genes , including those involved in cell growth, apoptosis, and inflammation.

NR1H2 is a key regulator of the hematopoietic stem cell (HSC) proliferation. It has been shown to play a role in the regulation ofHSC self-renewal and differentiation, and it has been linked to the development of various diseases, including cancer.

NR1H2 is also involved in the regulation of cell apoptosis, which is the process by which cells die naturally. When cells reach a certain level of stress or damage, they undergo apoptosis to prevent further injury. NR1H2 is shown to play a role in the regulation of apoptosis by activating the Bcl-2 pathway.

NR1H2 is also involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function and the production of pro-inflammatory cytokines. This may contribute to its role in the development of various inflammatory diseases.

Due to its involvement in these critical cellular processes, NR1H2 has been identified as a potential drug target. Researchers are currently working to develop compounds that can specifically target NR1H2 and modulate its activity. These compounds are being tested for their potential therapeutic benefits in a variety of diseases, including cancer, arthritis, and neurodegenerative diseases.

In addition to its potential therapeutic applications, NR1H2 is also an important biomarker for several diseases. Its expression has been shown to be elevated in a variety of diseases, including cancer, and it has been used as a diagnostic marker for these diseases. This makes it an attractive target for researchers to study and develop new diagnostic tests.

Overall, NR1H2 is a protein that has significant implications for our understanding of cellular signaling and the development of various diseases. Further research is needed to fully understand its role and potential as a drug target and biomarker.

Protein Name: Nuclear Receptor Subfamily 1 Group H Member 2

Functions: Nuclear receptor that exhibits a ligand-dependent transcriptional activation activity (PubMed:25661920). Binds preferentially to double-stranded oligonucleotide direct repeats having the consensus half-site sequence 5'-AGGTCA-3' and 4-nt spacing (DR-4). Regulates cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8; DLDLR and LRP8. Interplays functionally with RORA for the regulation of genes involved in liver metabolism (By similarity). Induces LPCAT3-dependent phospholipid remodeling in endoplasmic reticulum (ER) membranes of hepatocytes, driving SREBF1 processing and lipogenesis (By similarity). Via LPCAT3, triggers the incorporation of arachidonate into phosphatidylcholines of ER membranes, increasing membrane dynamics and enabling triacylglycerols transfer to nascent very low-density lipoprotein (VLDL) particles (By similarity). Via LPCAT3 also counteracts lipid-induced ER stress response and inflammation, likely by modulating SRC kinase membrane compartmentalization and limiting the synthesis of lipid inflammatory mediators (By similarity). Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex (PubMed:20159957)

The "NR1H2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NR1H2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets